News
Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...
3d
Zacks Investment Research on MSNMRNA Stock Jumps on CDC's Revised RSV Vaccine RecommendationsShares of Moderna MRNA rose nearly 6% yesterday after the U.S. Centers for Disease Control and Prevention (“CDC”) adopted new ...
The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.
Everest Medicines unveils breakthroughs in AI+mRNA platform, reinforces global leadership in next-gen mRNA innovation: Hong Kong Monday, July 7, 2025, 10:00 Hrs [IST] Everest Medi ...
If we don’t invest in technologies like mRNA vaccines for pandemic influenza now, once a virus starts going human-to-human, ...
The author says the action creates mistrust of the committee’s vaccine recommendations and further increases patients’ and ...
We may or may not be out of the woods, but focusing on the short-term performance of stocks is not the best strategy.
Moderna this week announced positive data from a phase 3 trial of its messenger RNA vaccine against seasonal influenza, which ...
The US Food and Drug Administration’s top vaccine official overrode agency experts in May to recommend against the broad use ...
In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...
2don MSNOpinion
Vaccines have been rigorously tested, reviewed, and monitored for decades. They are one of the greatest success stories in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results